The World Health Organization said on October 14 that it has approved the monkeypox vaccine produced by the Danish-based Bavarian Nordic Company for young people aged 12 to 17. This group is considered susceptible to monkeypox. The WHO issued a statement on the same day saying that the monkeypox vaccine for young people passed the preliminary review on the 8th of this month. In the middle of last month, this vaccine was approved for use in people aged 18 and over. Bavaria Nordic is also preparing to conduct a clinical trial to evaluate the safety of this monkeypox vaccine for children aged 2 to 12, which may further expand the scope of application.

The World Health Organization said on October 14 that it has approved the monkeypox vaccine produced by the Danish-based Bavarian Nordic Company for young people aged 12 to 17. This group is considered susceptible to monkeypox. The WHO issued a statement on the same day saying that the monkeypox vaccine for young people passed the preliminary review on the 8th of this month. In the middle of last month, this vaccine was approved for use in people aged 18 and over. Bavaria Nordic is also preparing to conduct a clinical trial to evaluate the safety of this monkeypox vaccine for children aged 2 to 12, which may further expand the scope of application.